Trial Profile
An Open Label, Single Group, Long Term Safety Extension Trial of BI 655066/ABBV-066 (Risankizumab), in Patients With Moderately to Severely Active Crohn's Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Risankizumab (Primary) ; Risankizumab (Primary)
- Indications Crohn's disease
- Focus Adverse reactions
- Sponsors AbbVie; Boehringer Ingelheim
- 25 Jun 2019 Status changed from active, no longer recruiting to completed.
- 24 Oct 2018 Interim results presented at the 26th United European Gastroenterology Week
- 16 Oct 2018 According to an AbbVie media release, data will be presented at United European Gastroenterology (UEG) Week 2018.